Global Glioblastoma Multiforme Treatment Drugs Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global glioblastoma multiforme treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are fuelling the market growth include the growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios, which are anticipated to boost the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period. The increasing incidence of brain tumors is expected to drive the growth of the global glioblastoma multiforme treatment market over the forecast period.
The increasing approval for
novel therapy and combination therapy is expected to drive the market in the
coming years. For instance, in June 2019, the U.S. FDA approved Pfizer’s
Zirabev, a biosimilar for Avastin, for the treatment of recurrent glioblastoma,
NSCLC, and colorectal cancer, among others. In January 2020, the company launched
its product in the U.S.
To Request a Sample of our Report on Global Glioblastoma
Multiforme Treatment Drugs Market: https://www.omrglobal.com/request-sample/glioblastoma-multiforme-treatment-drugs-market
The global glioblastoma multiforme treatment drugs
market analysis includes some of the key market players such as Sanofi S.A.,
Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., and Johnson
& Johnson (Janss en Pharmaceuticals), among others. To maintain a strong
position in the market, these market players are adopting various strategic
moves, such as product launches, partnerships, collaborations, and mergers and
acquisitions. For instance, in November 2019, the U.S. FDA accepted Samsung’s
BLA application for its SB8 bevacizumab biosimilar candidate, which will
increase the potential to launch products in the coming years.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Bausch Health Companies
Inc., NestlƩ (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris
Therapeutics, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Glioblastoma Multiforme Treatment Drugs Market is
Available at: https://www.omrglobal.com/industry-reports/glioblastoma-multiforme-treatment-drugs-market
Global Glioblastoma Multiforme Treatment Drugs Market by Segment
By Treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Others
By Drug Class
• Temozolomide
• Bevacizumab
• Lomustine
• Others
By End-Use
• Hospitals
• Clinics
• Ambulatory Surgical
Centers
Global Glioblastoma Multiforme Treatment Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment